Detalles de la búsqueda
1.
RX-5902, a novel ß-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
BMC Cancer
; 20(1): 1063, 2020 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33148223
2.
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Mol Cancer Ther
; 21(3): 397-406, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965958
3.
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.
Cancers (Basel)
; 12(3)2020 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32204315
4.
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Clin Cancer Res
; 26(17): 4633-4642, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32414750
5.
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ß-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Mol Cancer Ther
; 18(11): 1916-1925, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31488700
Resultados
1 -
5
de 5
1
Próxima >
>>